Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 2 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nuritas Limited has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 1 distinct art unit, so the docket is concentrated in one technical assignment while being divided between examiner practices.
KOMATSU, LI N is the busiest examiner, with 2 pending actions. Examiner-specific coordination may help maintain consistency across that examiner's matters, while the common art-unit setting provides an additional basis for organized review.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 2 | 59.8% | +71.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 2 | 35.0% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635796 | PEPTIDES FOR TREATING MUSCLE ATROPHY | KONOPELSKI SNAVEL, SARA ELIZABETH | 93d overdue |
| 17795331 | TREATMENT OF PANX1 ASSOCIATES DISEASES | KONOPELSKI SNAVEL, SARA ELIZABETH | 2d overdue |
| 18743639 | GROWTH PROMOTING PEPTIDES, AND USES THEREOF | KOMATSU, LI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635796 | PEPTIDES FOR TREATING MUSCLE ATROPHY | KONOPELSKI SNAVEL, SARA ELIZABETH | 93d overdue |
| 17795331 | TREATMENT OF PANX1 ASSOCIATES DISEASES | KONOPELSKI SNAVEL, SARA ELIZABETH | 2d overdue |
| 18743639 | GROWTH PROMOTING PEPTIDES, AND USES THEREOF | KOMATSU, LI N | — |
| 18451560 | ANTI-INFLAMMATORY PEPTIDES, AND USES THEREOF | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1658 | 4 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18743639 | GROWTH PROMOTING PEPTIDES, AND USES THEREOF | KOMATSU, LI N | 1658 | §101§102§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18451560 | ANTI-INFLAMMATORY PEPTIDES, AND USES THEREOF | KOMATSU, LI N | 1658 | §112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 17795331 | TREATMENT OF PANX1 ASSOCIATES DISEASES | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112Other | Non-Final OA | 2d overdue | Pending | Jul 26, 2022 |
| 17635796 | PEPTIDES FOR TREATING MUSCLE ATROPHY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§112 | Final Rejection | 93d overdue | Pending | Feb 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuritas Limited has 4 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Li N Komatsu has the most, with 2 of Nuritas Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
